Skip to main content

Table 1 Cisplatin-based conventional chemotherapy regimens and their efficacy against malignant pleural mesothelioma

From: A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report

Lead author/reference

Chemotherapy regimen

Admissions interval (median courses)

Number of patients

Response rate

Median survival (months)

Vogelzang [14]

Cisplatin (75mg/m2 on day one)/pemetrexed (500mg/m2 on day one)

Every three weeks, 6.0 courses

226

41 percent

12.1

Nakano [15]

Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15)

Every four weeks, 2.6 courses

15

27 percent

6.5

Tsavaris [16]

Cisplatin (100mg/m2 on day one)/vinblastine (6mg/m2 on days one and eight)

Every four weeks, 4.0 courses

20

25 percent

N/A

Ardizzoni [17]

Cisplatin (60mg/m2 on day 1)/doxorubicin (60mg/m2 on day one)

Every three to four weeks, 3.0 to 4.0 courses

26

25 percent

10

Nowak [18]

Cisplatin (100mg/m2 on day one)/gemcitabine (1000mg/m2 on days one, eight, and 15)

Every four weeks, 4.0 courses

53

33 percent

11.2

Present report

Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15)

One course with hyperthermia

 

Complete response

>84

  1. N/A, not applicable.